Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 22, 2025Human GenomicsOpen Access

Clinical and prognostic significance of m6A hypomethylation and IGF2BP3 overexpression in gastric cancer: an integrated epigenomic-transcriptomic analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXiangchen HuZWZhe WangYKYouwei Kou

Discussion

Loading...

Member takes

Overview

Transcriptome analysis reveals m6A dysregulation and IGF2BP3 as a prognostic marker in gastric cancer, suggesting potential therapeutic targets.

Key Points

  • m6A hypomethylation significantly affects gastric cancer progression, highlighting its role in disease mechanisms.
  • Transcriptome-wide analysis identified 271 reduced m6A peaks in gastric cancer tissues, implicating epitranscriptomic changes.
  • Elevated IGF2BP3 expression was found to correlate with lymph node involvement and advanced TNM staging in patients.
  • These findings support IGF2BP3 as a promising prognostic biomarker and potential therapeutic target in gastric cancer.

Cite This Study

Hu et al. (2025) studied this question.

synapsesocial.com/papers/68af76b27567bf4f94fef826https://doi.org/10.1186/s40246-025-00802-0
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Influence of Epigenetic Regulators Expression on Gastric Cancer Prognosis2025
  2. 2M6A RNA METHYLATION AS A THERAPEUTIC TARGET IN HIGH GRADE GLIOMA2025
  3. 3METTL3-mediated m6A modification of DNMT1 enhances ovarian cancer progression2025
  4. 4Dysregulated <scp>RNA m6A</scp> Methylation Contributes to the Metastasis of Gallbladder Cancer Through <scp>miR</scp>‐146a‐5p2025
  5. 5ZC3H13 mediates N6-methyladenosine modification of SNTB1 to promote epithelial-mesenchymal transition in gastric cancer2025